Plasma levels of 8-epiPGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease

Feillet‐Coudray, Christine; Tourtauchaux, R.; Niculescu, Michel; Rock, Edmond; Tauveron, Igor; Alexandre-Gouabau, Marie Cécile; Rayssiguier, Yves; Jalenques, Isabelle; Mazur, Andrzej

doi:10.1016/s0891-5849(99)00096-9

Cited by 88 publications

(54 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results are reported in the literature concerning plasma TAC measurement in AD patients (Sinclair et al 1998;Feillet-Coudray et al 1999;Pulido et al 2005), however other studies have shown a lower plasma TAC in AD patients (Reppetto et al 1999;Serra et al 2001;Guidi et al 2006).…”

Section: Discussionsupporting

confidence: 89%

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Maccioni¹

2008

NDT

View full text Add to dashboard Cite

Abstract:Oxidative stress has been implicated in the progression of a number of neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis. We carried out an in-depth study of cognitive impairment and its relationships with oxidative stress markers such as ferric-reducing ability of plasma (FRAP), plasma malondialdehyde and total antioxidative capacity (TAC), as well as cholesterol parameters, in two subsets of subjects, AD patients (n = 59) and a control group of neurologically normal subjects (n = 29), attending the University Hospital Salvador in Santiago, Chile. Cognitive impairment was assessed by a set of neuropsychological tests (Mini-Mental State Examination, Boston Naming Test, Ideomotor Praxia by imitation, Semantic Verbal Fluency of animals or words with initial A, Test of Memory Alteration, Frontal Assessment Battery), while the levels of those oxidative stress markers and cholesterol metabolism parameters were determined according with standard bioassays in fresh plasma samples of the two subgroups of patients. No signifi cant differences were observed when the cholesterol parameters (low-, high-density lipoprotein, total cholesterol) of the AD group were compared with normal controls. Interestingly, a correlation was evidenced when the levels of cognitive impairment were analyzed with respect to the plasma antioxidant capacity (AOC) of patients. In this context, the subset of subjects exhibiting cognitive impairment were divided into two subgroups according with their Global Dementia Scale performance: a subgroup with mild AD and a subgroup with moderate to severe AD. Signifi cant differences in AOC were found between subgroups. The different correlations between cognitive impairment of subgroups of subjects with the oxidative stress profi le are discussed in the context of AD pathogenesis.

show abstract

Section: Discussionsupporting

confidence: 89%

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Maccioni¹

2008

NDT

View full text Add to dashboard Cite

show abstract

“…Data on the correlation between age of the subjects and 15-F 2t -IsoP levels are conflicting. Whereas a positive association with age was observed in one small study (28), no effect of age was found in another (29). Data on the effect of age on 8-oxodG levels are also conflicting with both no effect (30) and positive correlations being reported (31).…”

Section: Discussionmentioning

confidence: 99%

Relationship between Urinary 15-F2t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk

Rössner

Gammon

Terry

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

To evaluate the role of oxidative stress in breast cancer, we measured urinary levels of 15-F 2t -isoprostane (15-F 2t -IsoP) and 8-oxodeoxyguanosine (8-oxodG) in 400 cases and 401 controls, participants of the Long Island Breast Cancer Study Project. We also analyzed the effect of different factors that are associated with oxidative stress and might influence 15-F 2t -IsoP and 8-oxodG levels. We observed a statistically significant trend in breast cancer risk with increasing quartiles of 15-F 2t -IsoP levels [odds ratio (OR), 1.25; 95% confidence interval (95% CI), 0.81-1.94; OR, 1.53; 95% CI, 0.99-2.35; OR, 1.88; 95% CI, 1.23-2.88, for the 2nd, 3rd, and 4th quartile relative to the lowest quartile, respectively; P trend = 0.002]. Although it is possible that increased levels may reflect the stress associated with recent treatment, the positive association was also observed when the analyses were restricted to case women for whom chemotherapy and radiation therapy had not yet been initiated at the time of the urine collection. The association with the highest quartile compared with lowest quartile of 15-F 2t -IsoP was similar across strata of age, physical activity, fruit and vegetable intake, alcohol intake, cigarette smoking, body mass index, and menopausal status. We did not observe any association of breast cancer risk with 8-oxodG levels, but when cases with radiation treatment were removed from the analysis, a significant inverse trend (P = 0.04) was observed. Among controls, levels of 15-F 2t -IsoP were higher among current cigarette smokers but did not differ by the amount of physical activity, fruit and vegetable intake, alcohol intake, body mass index, and menopausal status. Among controls, levels of 8-oxodG were higher among postmenopausal women and current and former cigarette smokers but did not differ by the other factors. In summary, our results suggest that urinary markers of lipid peroxidation and oxidative DNA damage may be associated with breast cancer risk. (Cancer Epidemiol Biomarkers Prev 2006;15(4):639 -44)

show abstract

“…In Alzheimer's diseases, increased levels of F 2 -isoprostanes have been found specifically in the cerebrospinal fluid, neurons and brain tissues (23,89,90,112,113). One study also demonstrated increased levels in the urine and plasma (91), which was not confirmed in other studies (93,114). The reason for this inconsistency may be that biological samples were not taken at identical stages of the disease or that different drugs embroidered the outcome.…”

Section: Isoprostanes In Other Human Diseasesmentioning

confidence: 99%

The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target

Basu¹

2007

Food & Nutrition Research

View full text Add to dashboard Cite

Oxidative stress is believed to be one of the major factors behind several acute and chronic diseases, and may also be associated with ageing. Excess formation of free radicals in miscellaneous body environment may originate from endogenous response to cell injury, but also from exposure to a number of exogenous toxins. When the antioxidant defence system is overwhelmed, this leads to cell damage. However, the measurement of free radicals or their endproducts is tricky, since these compounds are reactive and short lived, and have diverse characteristics. Specific evidence for the involvement of free radicals in pathological situations has been difficult to obtain, partly owing to shortcomings in earlier described methods for the measurement of oxidative stress. Isoprostanes, which are prostaglandin-like bioactive compounds synthesized in vivo from oxidation of arachidonic acid, independently of cyclooxygenases, are involved in many human diseases, and their measurement therefore offers a way to assess oxidative stress. Elevated levels of F 2 -isoprostanes have also been seen in the normal human pregnancy, but their physiological role has not yet been defined. Large amounts of bioactive F 2 -isoprostanes are excreted in the urine in normal basal situations, with a wide interindividual variation. Their exact role in the regulation of normal physiological functions, however, needs to be explored further. Current understanding suggests that measurement of F 2 -isoprostanes in body fluids provides a reliable analytical tool to study oxidative stress-related diseases and experimental inflammatory conditions, and also in the evaluation of various dietary antioxidants, as well as drugs with radical-scavenging properties. However, assessment of isoprostanes in plasma or urine does not necessarily reflect any specific tissue damage, nor does it provide information on the oxidation of lipids other than arachidonic acid.

show abstract

Plasma levels of 8-epiPGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease

Cited by 88 publications

References 35 publications

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Relationship between Urinary 15-F2t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk

The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target

Contact Info

Product

Resources

About

Plasma levels of 8-epiPGF2α, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer’s disease

Cited by 88 publications

References 35 publications

Cognitive impairment and Alzheimer&rsquo;s disease: Links with oxidative stress and cholesterol metabolism

Cognitive impairment and Alzheimer&rsquo;s disease: Links with oxidative stress and cholesterol metabolism

Relationship between Urinary 15-F2t-Isoprostane and 8-Oxodeoxyguanosine Levels and Breast Cancer Risk

The enigma of in vivo oxidative stress assessment: isoprostanes as an emerging target

Contact Info

Product

Resources

About

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism

Cognitive impairment and Alzheimer’s disease: Links with oxidative stress and cholesterol metabolism